RT Journal Article
SR Electronic
T1 The EO771 mammary cancer cell line displays a luminal B phenotype and it is sensitive to anti-estrogen treatments
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 715201
DO 10.1101/715201
A1 Augustin Le Naour
A1 Yvonne Koffi
A1 Mariane Diab
A1 Delphine Le Guennec
A1 Stéphanie Rougé
A1 Sahar Aldekwer
A1 Nicolas Goncalves-Mendes
A1 Jeremie Talvas
A1 Marie-Chantal Farges
A1 Florence Caldefie-Chezet
A1 Marie-Paule Vasson
A1 Adrien Rossary
YR 2019
UL http://biorxiv.org/content/early/2019/07/25/715201.abstract
AB Despite decades of therapeutic trials, detection, many drugs available and numerous studies on breast cancer, it remains the most deadly cancer in women. In order to choose the most appropriate treatment and to know the prognosis of the patients, the breast cancer is divided into different subtypes using a molecular classification. Thus, the need to discover new effective therapy is necessary, requiring to have models to test them. The EO771 (also named E0771 or EO 771) murine mammary cancer cell line is originally isolated from a spontaneous tumor in C57BL/6 mouse. Although frequently used, this cell line remains poorly characterized. Therefore, the EO771 phenotype was investigated. Transcriptomic and protein analysis allowed to classify the EO771 as luminal B subtype and more precisely estrogen receptor α negative, estrogen receptor β positive, progesterone receptor positive and ErbB2 positive. This phenotype was associated to a sensitivity to anti-estrogen treatments such as tamoxifen, 4-hydroxy-tamoxifen, endoxifen and fulvestrant.